Skip to main content
Premium Trial:

Request an Annual Quote

Mark Bennett, Ronald Lindsay, Vincent Forlenza, Deborah Neff


Mark Bennett has become general manager for Asia Pacific of Newcastle upon Tyne, UK-based Nonlinear Dynamics, replacing Alan Koontz, who died last year. Bennett will retain his title and strategic management duties as CEO of Nonlinear’s US subsidiary, Nonlinear USA.


Ronald Lindsay has joined the board of directors of AnVil, based in Burlington, Mass. He is currently CSO and vice president of R&D at DiaDexus of San Francisco. Prior to that, he was senior vice president for biotherapeutics at Millennium Pharmaceuticals. Before that, he held positions at Regeneron, the

Sandoz Institute for Medical Research at University College

, London, and the National Institute of Medical Research in Mill Hill, London.


Vincent Forlenza has been appointed president of BD Biosciences, based in San Jose, Calif. Most recently, he was the company’s senior vice president for technology, strategy, and development. Forlenza succeeds Deborah Neff, who is leaving BD to pursue other opportunities. He holds a BS in chemical engineering from Lehigh University and an MBA from the Wharton Graduate School at the University of Pennsylvania.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.